Advances in Clinical and Experimental Medicine
2018, vol. 27, nr 3, March, p. 383–389
Publication type: original article
Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with anti-TNF therapy
1 Department of Internal Medicine and Rheumatology, School of Medicine in Katowice, Medical University of Silesia, Poland
Background. Fibulin-3 (Fib-3) is a new potential biomarker of articular cartilage metabolism.
Objectives. The aim of the study was to evaluate the effect of anti-TNF therapy on serum fibulin-3, cartilage oligomeric matrix protein (COMP), procollagen II C-propeptide (PIICP), and urinary C-terminal telopeptide of type II collagen (CTX-II) levels in relation to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients.
Material and Methods. In the study, 35 female patients with rheumatoid arthritis (RA) were investigated. The concentration of fibulin-3, COMP, PIICP, MRP8/14, and urinary CTX-II in serum was measured before and after anti-TNF therapy. Ten healthy women were investigated as the controls.
Results. The concentration of fibulin-3 in RA patients before treatment did not differ significantly from the concentration of fibulin-3 in the control group. A significantly higher concentration of fibulin-3 was noted prior to treatment in the group of women with a worse response to the therapy (non-responders) compared to the concentration of fibulin-3 in the healthy women. During the anti-TNF therapy, the serum fibulin-3 level decreased in patients. The fibulin-3 level correlated with CRP and ESR after anti-TNF treatment. Significant lowering of MRP8/14 was noted in the patients after anti-TNF therapy. No correlation between fibulin-3 and MRP8/14 was observed in the study group or in the control group.
Conclusion. During the anti-TNF therapy, the serum fibulin-3 level decreased in RA patients. Serum MRP8/14 concentration also decreased. No correlation between fibulin-3 and MRP8/14 was observed in the study group before and after the treatment. We found a poor correlation between serum fibulin-3 and other cartilage metabolism biomarkers after anti-TNF therapy.
rheumatoid arthritis, fibulin-3, calprotectin
- Rousseau JC, Garnero P. Biological markers in osteoarthritis. Bone. 2012;51:265–277.
- Zhang Y, Marmorstein LY. Focus on molecules: Fibulin-3 (EFEMP1). Exp Eye Res. 2010;90:374–375.
- Wakabayashi T, Matsumine A, Nakazora S, et al. Fibulin-3 negative- ly regulates chondrocyte differentiation. Biochem Biophys Res Com- mun. 2010;391:1116–1121.
- Henrotin Y, Gharbi M, Mazzucchelli G, Dubuc JE, De Pauw E, Deberg M. Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of teoarthritis. Arthritis Rheum. 2012;64:2260–2267.
- Larrson E, Erlandsson Harris H, Lorentzen JC, et al. Serum concen- trations of cartilage oligomeric matrix protein, fibrinogen and hyal- uronan istinguish inflammation and cartilage destruction in exper- imental rthritis in rats. Rheumatology. 2002;41:996–1000.
- Elsaid KA, Chichester CO. Review: Collagen markers in early arthritic diseases. Clin Chim Acta. 2006;365:68–77.
- Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and diseases activity in patients with inflam- matory rheumatic disaeses. J Rheumatol. 1994;21:733–738.
- García-Arias M, Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis. Mol Diagn Ther. 2013;17:49–56.
- Möller B, Scherer A, Förger F, Viliger P, Finckh A. Anaemia may add information to standardized disease activity assessment to predict radiographic damage in rheumatoid arthritis: A prospective cohort study. Ann Rheum Dis. 2014;73:691–696.
- Marotte H, Gineyts E, Miossec P, Delmas PD. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68:1197–1200.
- 11. Crnkic M, Mansson B, Larsson L, Geborek P, Heinegard D, Saxne T. Serum cartilage oligomeric matrix protein (COMP) decreases in rheu- matoid arthritis patients treated with infliximab or etanercept. Arthri- tis Res Ther. 2003;5:181–185.